Le Lézard
Classified in: Health
Subjects: PDT, FDA

U.S. grants marketing approval for the new Scrambler Therapy® Technology ST-5A Medical Device for the non-invasive treatment of neuropathic and cancer pain (MDR 745/2017)


ROME, Feb. 17, 2021 /PRNewswire/ -- The next generation Scrambler Therapy® Technology ST-5A has received marketing approval from the FDA (K201458). This new device replaces the previous two generations known as "Calmare®" and "Scrambler Therapy® Technology MC-5A" respectively, which are no longer in production.

Scrambler Therapy® device ST-5A (Made in Italy). Replaces the previous model MC-5A.

Indications for Use (MDR 745/2017)

The specific indications for use are clinical results from scientific literature indexed and published in peer review scientific journals,  based exclusively on this technology are:

In general, this device is indicated for all forms of severe chronic pain, specifically pain that does not respond to other pharmacological or non-pharmacological treatments, including opioids.

This third generation medical device is made entirely in Italy, where the scientific research that generated this technology originated. Among the most significant innovations are a modernized design, integrated compatibility dual power supply, quality guaranteed by the strict European Medical Device Regulation, and the stylistic and technological tradition of "Made in Italy".

About Delta International Service & Logistics

DIS&L is the agency created for the international development of Scrambler Therapy® Technology, and the selection of Scrambler Therapy Technology ST-5A Medical Device distributors in all international areas. DIS&L through its law firm is the only company authorized to sign international exclusive agreements, provide maintenance and client support for technical treatment training and other logistical needs.

www.st-team.eu

About Scrambler Therapy®

Scrambler Therapy® scientific research and development technology has been developed in Italy by Professor Giuseppe Marineo, who is the sole owner of its intellectual property rights. The official "Scrambler Therapy"® scientific and clinical information website is:

www.scramblertherapy.org/

 

SOURCE Delta International Services & Logistics s.r.l.


These press releases may also interest you

at 19:05
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:42
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...

at 18:18
Targeting a Solution is an insightful and impactful fireside discussion dedicated to ending Veteran suicide that will have its next iteration on April 20th, 2024, in Kannapolis, NC hosted by The Independence Fund. The panel will feature four-term...

at 18:15
Equality Health Foundation, the philanthropic partner of Equality Health LLC and an organization dedicated to advancing health equity and improving well-being access for underserved communities, proudly announces its expansion into Virginia and...

at 18:01
Aflac Incorporated announced today that it has revised the time of its first quarter webcast teleconference call on Thursday, May 2, 2024 to 7:00 a.m. (ET), which is one hour earlier than the originally scheduled 8:00 a.m. start time, to avoid...

at 17:48
On Wednesday, April 17, the San Joaquin Valley Health Fund (SJVHF) launched "Equity on the Road" a multi-city series of community town halls to deepen local understanding of state issues and to advocate for more resources in the San Joaquin Valley....



News published on and distributed by: